Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Statistics
  • Help & Advice
University of Warwick

The Library

  • Login

The potential cost-effectiveness of acellular pertussis booster vaccination in England and Wales

Tools
- Tools
+ Tools

UNSPECIFIED (2002) The potential cost-effectiveness of acellular pertussis booster vaccination in England and Wales. VACCINE, 20 (9-10). pp. 1316-1330. ISSN 0264-410X

Full text not available from this repository.

Abstract

A cost-effectiveness analysis of the introduction of acellular pertussis booster doses at either 4 or 15 years of age was performed. A transmission dynamic model was used to predict the level of indirect protection in those too young to be vaccinated. Multivariate sensitivity analyses were performed. In England and Wales there are an estimated 35,000 general practitioner (GP) consultations, 5500 inpatient days, and nine deaths annually attributable to pertussis. despite high levels of coverage for the primary course (similar to95%). Around 80111 of the bed-days and 90% of the deaths occur in those too young to be immunised (<3 months of age). The introduction of acellular booster doses at 4 years is expected to reduce morbidity and mortality in the younger age groups by 40-100%, and at 15 years by 0-100%. From the perspective of the health care provider. roughly 50% of the simulations result in a cost per life-year gained of less than pound10,000 for vaccination at 4 years, the corresponding proportion for vaccination at 15 years being only 35%. Apart from the degree of indirect protection the model was most sensitive to the discount rate. the price of the vaccine, and the mortality rate. Significant uncertainty remains regarding the epidemiology of pertussis and the impact of booster doses. Nevertheless, the introduction of acellular boosters, particularly at 4 years, has the potential to be cost-effective in the UK. (C) 2002 Elsevier Science Ltd. All rights reserved.

Item Type: Journal Article
Subjects: Q Science > QR Microbiology > QR180 Immunology
R Medicine
Journal or Publication Title: VACCINE
Publisher: ELSEVIER SCI LTD
ISSN: 0264-410X
Date: 31 January 2002
Volume: 20
Number: 9-10
Number of Pages: 15
Page Range: pp. 1316-1330
Publication Status: Published
URI: http://wrap.warwick.ac.uk/id/eprint/11241

Data sourced from Thomson Reuters' Web of Knowledge

Request changes to a record

Actions (login required)

View Item View Item
twitter

Email us: publications@warwick.ac.uk
Contact Details
About Us